0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Special Feature |

Picture of the Month—Diagnosis FREE

[+] Author Affiliations

Section Editor: Samir S. Shah, MD
Section Editor: Albert C. Yan, MD

More Author Information
Arch Pediatr Adolesc Med. 2008;162(7):690. doi:10.1001/archpedi.162.7.690.
Text Size: A A A
Published online

DENOUEMENT AND COMMENT: ERYTHROPOIETIC PROTOPORPHYRIA

In this case, the key to diagnosis was the localization of the rash in phototherapy-exposed areas. The differential diagnosis of photosensitivity in the newborn includes a wide range of disorders including those related to DNA-repair syndromes (xeroderma pigmentosum, Rothmund-Thomson syndrome, Bloom syndrome, and Cockayne syndrome), transplacentally transferred collagen vascular disorders (neonatal lupus erythematosus and drug-induced lupus erythematosus), and the porphyrias.

In this case, the purpuric nature of the photodistributed skin findings suggested a porphyrin-related mechanism. While transient erythroporphyria of the newborn and transfusion-associated photosensitivity may present with similar findings, these tend to occur in the context of exchange transfusions, which did not occur in this case. Laboratory data obtained on day 6 of the infant's life revealed an elevated protoporphyrin level of 1089 μg/dL (normal, 16-60 μg/dL [to convert to micromoles per liter, multiply by 0.0178]). The patient also had normal serum levels of iron and hemoglobin and was negative for the antinuclear antibody. At 10 weeks of age, the infant's whole-blood porphyrin level demonstrated a persistent elevation in protoporphyrin levels, and a diagnosis of erythropoietic protoporphyria (EPP) was made. Elevations in maternal protoporphyrin levels were subsequently confirmed.

Erythropoietic protoporphyria is a disorder defined by a deficiency in ferrochelatase, the enzyme responsible for the last step in the porphyrin pathway that produces heme. Erythropoietic protoporphyria, inherited in an autosomal dominant fashion, is the most common childhood porphyria and typically presents between ages 2 and 5 years, when the amount of sun exposure increases. Parents may report childhood irritability and crying on exposure to sunlight. A history of skin pain, burning, tingling, or itching within 1 hour after being exposed to the sun is typical.1This sensation is usually followed by acute changes of erythema, edema, urticaria, and purpura of the exposed skin developing several hours after exposure. Chronic skin changes in EPP appear on sun-exposed areas such as the face, especially on the ears and nose, in the form of erosions, scars, or waxy skin thickening. Patients may display findings of hyperkeratosis and leathery skin on the dorsum of the hands and knuckles, known as velvet knuckles. Other physical examination findings can include opacification of the nail plates, onycholysis, and tenderness of the nail beds. Besides having skin changes, patients with EPP are prone to gallstones at an unusually early age. Liver disease is uncommon, but liver function testing should be monitored, as hepatic dysfunction may be severe enough to require liver transplantation.24

The diagnosis of EPP is made by demonstrating an elevation in free erythrocyte proporphyrin. Most other forms of cutaneous porphyria, in which water-soluble porphyrins accumulate in the skin, will have porphyrins detectable in the urine. The pathophysiology of EPP is based on the interaction between protoporphyrins in the skin and visible light. As a lipophilic porphyrin, protoporphyrin leads to phototoxicity and blood vessel damage in the dermis on interacting with visible light with wavelengths in the Soret band (400-440 nm). Free radicals produced in the dermis may ultimately lead to pain, swelling, redness, and erosions.

The most important step in the management of EPP is avoiding exposure to sunlight and using topical sunscreens. Some sources recommend dihydroxyacetone and iron oxide along with traditional UV-B/UV-A sunscreen.5Oral β-carotene may be used to increase sun tolerance and provide more systemic protection. Doses of 120 to 180 mg daily are recommended. Effects may be expected within 1 to 3 months. During operations in patients with EPP, exposure of the internal organs to the artificial lights used in the operating room can precipitate a deadly reaction.

Case reports of a photodistributed rash following phototherapy have been documented in children with congenital erythropoietic porphyria,68those with an entity known as transient porphyria of the newborn,9,10as well as in association with exchange transfusions.11This article therefore documents the first case of EPP presenting in the neonatal period following visible light phototherapy.

Return to .

Correspondence:Patrick McMahon, MD, Children's Hospital of Philadelphia, 34th St and Civic Center Blvd, Philadelphia, PA 19104 (mcmahonpa@email.chop.edu).

Accepted for Publication:June 19, 2007.

Author Contributions:Study concept and design: McMahon and Yan. Acquisition of data: McMahon and Yan. Drafting of the manuscript: McMahon. Critical revision of the manuscript for important intellectual content: McMahon.

Financial Disclosure:None reported.

Murphy  GM Diagnosis and management of the erythropoietic porphyrias. Dermatol Ther 2003;16 (1) 57- 64
PubMed Link to Article
Gross  UFrank  MDoss  MO Hepatic complications of erythropoietic protoporphyria. Photodermatol Photoimmunol Photomed 1998;14 (2) 52- 57
PubMed Link to Article
Behrman  REedKliegman  RedJenson  HBed Nelson Textbook of Pediatrics. 17th ed. Philadelphia, PA W.B. Saunders2004;504
Dombeck  TASatonik  R The porphyrias. Emerg Med Clin North Am 2005;23 (3) 885- 899
PubMed Link to Article
Deleo  V Sunscreen use in photodermatoses. Dermatol Clin 2006;24 (1) 27- 33
PubMed Link to Article
Soylu  AKavukcu  STurkmen  M Phototherapy sequela in a child with congenital erythropoietic porphyria. Eur J Pediatr 1999;158 (6) 526- 527
PubMed Link to Article
Tönz  OVogt  JFilippini  LSimmler  FWachsmeth  EDWinterhalter  KH Severe light dermatosis following phototherapy in a newborn infant with congenital erythropoietic urophyria. Helv Paediatr Acta 1975;30 (1) 47- 56
PubMed
Verstraeten  LVan Regemorter  NPardou  A Biochemical diagnosis of a fatal case of Gunther's disease in a newborn with hydrops foetalis. Eur J Clin Chem Clin Biochem 1993;31 (3) 121- 128
PubMed
Crawford  RILawlor  EWadsworth  LDPrendiville  JS Transient erythroporphyria of infancy. J Am Acad Dermatol 1996;35 (5, pt 2) 833- 834
PubMed Link to Article
Mallon  EWojnarowska  FHope  P  et al.  Neonatal bullous eruption as a result of transient porphyrinemia in a premature infant with hemolytic disease of the newborn. J Am Acad Dermatol 1995;33 (2, pt 2) 333- 336
PubMed Link to Article
Paller  ASEramo  LFarrell  EMillard  DHonig  PCunningham  B Purpuric phototherapy-induced eruption in transfused neonates: relation to transient porphyrinemia. Pediatrics 1997;100 (3, pt 1) 360- 364
PubMed Link to Article

Figures

Tables

References

Murphy  GM Diagnosis and management of the erythropoietic porphyrias. Dermatol Ther 2003;16 (1) 57- 64
PubMed Link to Article
Gross  UFrank  MDoss  MO Hepatic complications of erythropoietic protoporphyria. Photodermatol Photoimmunol Photomed 1998;14 (2) 52- 57
PubMed Link to Article
Behrman  REedKliegman  RedJenson  HBed Nelson Textbook of Pediatrics. 17th ed. Philadelphia, PA W.B. Saunders2004;504
Dombeck  TASatonik  R The porphyrias. Emerg Med Clin North Am 2005;23 (3) 885- 899
PubMed Link to Article
Deleo  V Sunscreen use in photodermatoses. Dermatol Clin 2006;24 (1) 27- 33
PubMed Link to Article
Soylu  AKavukcu  STurkmen  M Phototherapy sequela in a child with congenital erythropoietic porphyria. Eur J Pediatr 1999;158 (6) 526- 527
PubMed Link to Article
Tönz  OVogt  JFilippini  LSimmler  FWachsmeth  EDWinterhalter  KH Severe light dermatosis following phototherapy in a newborn infant with congenital erythropoietic urophyria. Helv Paediatr Acta 1975;30 (1) 47- 56
PubMed
Verstraeten  LVan Regemorter  NPardou  A Biochemical diagnosis of a fatal case of Gunther's disease in a newborn with hydrops foetalis. Eur J Clin Chem Clin Biochem 1993;31 (3) 121- 128
PubMed
Crawford  RILawlor  EWadsworth  LDPrendiville  JS Transient erythroporphyria of infancy. J Am Acad Dermatol 1996;35 (5, pt 2) 833- 834
PubMed Link to Article
Mallon  EWojnarowska  FHope  P  et al.  Neonatal bullous eruption as a result of transient porphyrinemia in a premature infant with hemolytic disease of the newborn. J Am Acad Dermatol 1995;33 (2, pt 2) 333- 336
PubMed Link to Article
Paller  ASEramo  LFarrell  EMillard  DHonig  PCunningham  B Purpuric phototherapy-induced eruption in transfused neonates: relation to transient porphyrinemia. Pediatrics 1997;100 (3, pt 1) 360- 364
PubMed Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles